SEOM clinical guideline for treatment of kidney cancer (2017)
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Méndez-Vidal, M. J. (Instituto Maimónides de Investigación Biomédica de Córdoba)
Pérez-Gracia, J. L. (Clínica Universidad de Navarra)
Sepúlveda-Sánchez, J. M. (Hospital Universitario 12 de Octubre (Madrid))
Campayo, M. (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Chirivella, Isabel (Hospital Clínic Universitari (València))
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge)
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid))
Suárez, Cristina (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Date:	2017
Abstract:	The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Kidney cancer ; Systemic therapy ; Molecular pathology
Published in:	Clinical & translational oncology, Vol. 20 (november 2017) , p. 47-56, ISSN 1699-3055

DOI: 10.1007/s12094-017-1765-4
PMID: 29134564

10 p, 402.2 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles